You are here

Amarin

Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own

Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own

Fierce Pharma

Flag link:

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

Here's Why Amarin Tumbled 67.7% in the First Half of 2020

Motley Fool

Flag link:

A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

Fierce Pharma

Flag link:

FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?

FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?

Endpoints

Flag link:

Can Amarin's Stock Recover From Its 70% Implosion?

Can Amarin's Stock Recover From Its 70% Implosion?

Motley Fool

Flag link:

Are Amarin's Blockbuster Dreams Over?

Are Amarin's Blockbuster Dreams Over?

Motley Fool

Flag link:

Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Fierce Pharma

Flag link:

Drug makers grounding salespeople as coronavirus impact on business spreads

Drug makers grounding salespeople as coronavirus impact on business spreads

Stat

Flag link:

Why Amarin Stock Plunged in February

Why Amarin Stock Plunged in February

Motley Fool

Flag link:

Amarin aims for Vascepa boom with doubled sales force nearly in place

Amarin aims for Vascepa boom with doubled sales force nearly in place

Fierce Pharma

Flag link:

Amarin: Is It Time to Test the Waters?

Amarin: Is It Time to Test the Waters?

Motley Fool

Flag link:

With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds

With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds

Fierce Pharma

Flag link:

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

Fierce Pharma

Flag link:

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

Fierce Pharma

clinical trials

Flag link:

Fish oil pill for NASH? Dutch biotech scores $40M injection to make a mark in the bustling field

Fish oil pill for NASH? Dutch biotech scores $40M injection to make a mark in the bustling field

Endpoints

NorthSea Therapeutics

Flag link:

Vascepa sparkle set to light up Amarin's fourth quarter revenue

Vascepa sparkle set to light up Amarin's fourth quarter revenue

Endpoints

Flag link:

Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Yahoo/Marketwatch

Flag link:

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Fierce Pharma

Flag link:

2 Top Biotech Buyout Candidates

2 Top Biotech Buyout Candidates

Motley Fool

Aurinia Pharmaceuticals

Flag link:

4 FDA Dates Biotech Investors Should Circle in December

4 FDA Dates Biotech Investors Should Circle in December

Motley Fool

anti-inflammatories

Bausch Health Companies

Intra-Cellular Therapies

Flag link:

Pages